Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.
Also called NCT04415164
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 480 participants
- Sponsor
- Registry
-
NCT04415164
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04415164. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-29 (actual); primary completion 2022-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
- Acronym
- EXPECT
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Xueshuantong lyophilized powder
- Intervention (Drug)
- Placebo
- Intervention (Other)
- Guidelines-based standard care
- Lead sponsor
- Dongzhimen Hospital, Beijing
- Collaborator
- Tianjin University of Traditional Chinese Medicine
Record details
- Record id
cardio:ct-nct04415164- Content hash
15bd787d250db4e4d9146547a8ce6008b4e2423fe89d21774231b2d9a5574939